By the end of this video, you'll be able to define
a PK/PD relationship. You will be able to
list the roles of PK/PD studies during
drug discovery. You will also be able
to distinguish between a direct and indirect
PK/PD relationship. Pharmacokinetics, PK, is often described as what
the body does to the drug, comprising absorption, distribution, metabolism,
and elimination. It can be captured
by a concentration, time curve as shown in
the upper left graph. Pharmacodynamics, PD, can be described as what
the drug does to the body. PD is often quantified
using biomarkers as indicators of the biological
effects of the drug. Biomarkers can range from electrical signals in
the millisecond range to enzymes changing over hours to tumor size changing
over weeks or months. A drug's PD is
captured by an effect, time curve as shown in the
upper right hand graph. PK/PD then is the
relationship between pharmacokinetics and pharmacodynamics
linking concentration, effect, and time, as shown in the bottom graph. PK/PD evolves throughout the
drug development process. During pre-clinical
phases, PK/PD can be used to design
pharmacology studies, select the best compound, ensure target engagement, and
predict PK/PD for humans. In clinical phases, PK/PD
can be used to define PK/PD sampling times and to find the efficacious dose and
dosing frequency in human. There are two basic types of PK/PD relationships,
direct and indirect. Let's start with a
direct relationship. A direct effect is a
simple relationship with no time delay between PK/PD. This relationship can be seen in the upper
right-hand plot, where the blue line
represents concentration, and the red line, the effect or response. The two lines move
simultaneously with effect, increasing indirect
relation to concentration, and both concentration and
affect peak at the same time. This relationship can
then be captured as a classical E_max curve shown
in the bottom right plot, where concentration and effect are plotted to
determine an EC50. The second relationship is
an indirect relationship. This relationship is
more complex and shows a delay between PK/PD. As seen in the top graph, drug concentration
typically peaks first, with the drug effect peaking
at a later time point. The observed time delay can
be due to several factors, such as time for the drug to distribute from blood
to the target site, presence of an
active metabolite, the PDM point, maybe part of a cascade or a downstream marker or effect, or there may be up or
down-regulation of the receptor. In this situation, plotting the response or effect against concentration in the lower-left gives what's called
a hysteresis curve, a mathematical or PK/PD model can collapse the
hysteresis curve to generate a dose-response
relationship and determine an EC50. Understanding a
PK/PD relationship requires multiple studies. One example is a dose
fractionation study, which can address
whether the PD is driven by C_max or AUC. Those fractionation studies
require two groups. Group 1, shown in
blue on the graph, and Group 2 in red. Group 1 receives a single dose, whereas Group 2 receives a fractionated dose which is
administered three times. This achieves the same AUC as observed for the blue group, yet with a different C_max. In this type of study, if the PD effect is unchanged, then the effect is AUC-driven. If the PD effect is
lower in Group 2, then the effect is C_max-driven. AUC-driven effects
are more commonly observed than
C_max-driven effects, however, this depends on the drug type and
mechanism of action. Other drivers of PD exist, but they are outside the
scope of our discussion. We have now defined a PK/PD relationship
while describing how the understanding of
PK/PD relationships contribute to drug discovery. We focused on the two
most common types of PK/PD relationships,
direct and indirect, and discussed how to
distinguish between C_max and AUC-driven
pharmacodynamics